PDP-Miner identifies depolymerase activity in phage tail proteins across bacterial genomes, suggesting new antibiotic alternatives.
Motivation Antibiotic resistance is predicted to become the leading cause of human mortality by 2050. Despite this, no other major antibiotic class has been approved for medical use since 1987. Nevertheless, phage tail proteins offer a promising alternative, given their depolymerase activity toward outer membrane polysaccharides. Several pathogenic bacteria harbor prophages, thus making these prophages’ molecular target already known. Application We therefore developed a wrapper for an existing machine learning-based phage depolymerase prediction tool (Depolymerase-Predictor), called PDP-Miner, which annotates phage tail proteins ab initio, detects depolymerase activity within this candidate protein subset, and then performs post-hoc validation by annotating protein domains thereby allowing the user to investigate for protein domains indicative of depolymerase activity. This tool allowed identification of 10 high confidence phage depolymerase gene candidates across all 1,294 Pseudomonas genomes available on the International Pseudomonas Consortium Database while also accurately reporting depolymerases in known phage genomes, similarly to other software like PhageDPO or DepoScope. Availability and Implementation Source code is freely available for download at http://www.github.com/jeffgauthier/pdpminer. Implemented in Bash, supported on native Linux or WSL and supports submitting subtasks to a computing workload manager. Requires Miniconda3 to install dependencies. This software is free and open source under the GNU General Public License v3.0. Supplementary information Supplementary data are available at Bioinformatics online.
No takes yet. Share an insight, caveat, or question.
Gauthier et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: